Orum Therapeutics (KRX: 475830)
Who is buying Orum Therapeutics?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩4.5bn ($3M) of Orum Therapeutics, the 78th largest foreign net purchase among 1828 KOSDAQ stocks. Institutions net sold ₩18.3bn ($14M) and retail investors net bought ₩14.5bn ($11M) over the same window. Foreigners were net buyers on 10 of the 20 sessions.
Foreign investors hold 7.6% of Orum Therapeutics' listed shares (KRX ownership data as of Oct 13, 2026), up from 7.05% twenty sessions earlier and 1.82% a year ago.
The stock closed at ₩17,020 on Oct 13, 2026: -68.36% over 20 sessions, -85.82% year-to-date, -51.65% over one year. The 52-week range is ₩16,490 – ₩146,600.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩17,020 | +₩1.5bn | +₩0.1bn | ₩-2.6bn |
| 2026-10-12 | ₩17,820 | +₩0.5bn | ₩-0.2bn | ₩-1.1bn |
| 2026-10-08 | ₩19,270 | ₩0.0bn | ₩-0.1bn | +₩0.1bn |
| 2026-10-07 | ₩20,600 | ₩-0.3bn | +₩0.2bn | +₩0.1bn |
| 2026-10-06 | ₩20,450 | +₩2.1bn | ₩-2.7bn | +₩0.7bn |
| 2026-10-02 | ₩21,150 | ₩-5.0bn | ₩-2.8bn | +₩6.7bn |
| 2026-10-01 | ₩23,350 | +₩3.1bn | +₩0.5bn | ₩-3.3bn |
| 2026-09-30 | ₩22,150 | +₩2.9bn | ₩-2.4bn | ₩-0.6bn |
| 2026-09-29 | ₩22,500 | +₩2.3bn | ₩-2.7bn | +₩0.4bn |
| 2026-09-28 | ₩24,250 | ₩-0.6bn | ₩-0.2bn | +₩0.8bn |
| 2026-09-23 | ₩25,000 | ₩-0.7bn | ₩-0.2bn | +₩0.6bn |
| 2026-09-22 | ₩25,400 | ₩-5.2bn | +₩1.0bn | +₩4.0bn |
| 2026-09-21 | ₩27,300 | +₩3.1bn | ₩-8.7bn | +₩9.1bn |
| 2026-09-18 | ₩37,400 | +₩0.9bn | ₩-0.2bn | ₩-0.8bn |
| 2026-09-17 | ₩53,400 | ₩-0.9bn | +₩1.1bn | ₩-0.1bn |
| 2026-09-16 | ₩50,700 | ₩-0.2bn | +₩0.1bn | +₩0.0bn |
| 2026-09-15 | ₩50,500 | ₩-0.1bn | +₩0.2bn | ₩-0.1bn |
| 2026-09-14 | ₩49,950 | +₩0.9bn | ₩-1.0bn | +₩0.0bn |
| 2026-09-11 | ₩51,000 | +₩1.1bn | ₩-1.7bn | +₩0.6bn |
| 2026-09-10 | ₩53,100 | ₩-1.0bn | +₩1.3bn | ₩-0.2bn |
| 2026-09-09 | ₩53,800 | ₩-0.2bn | +₩0.1bn | +₩0.1bn |
| 2026-09-08 | ₩53,000 | +₩0.3bn | ₩-0.3bn | +₩0.0bn |
| 2026-09-07 | ₩54,100 | +₩1.9bn | ₩-2.8bn | +₩0.9bn |
| 2026-09-04 | ₩55,900 | ₩-0.5bn | ₩-0.8bn | +₩1.4bn |
| 2026-09-03 | ₩54,500 | +₩1.9bn | ₩-1.3bn | ₩-0.5bn |
| 2026-09-02 | ₩56,300 | +₩3.8bn | ₩-4.2bn | +₩0.4bn |
| 2026-09-01 | ₩59,200 | ₩-0.2bn | ₩-5.2bn | +₩5.9bn |
| 2026-08-31 | ₩65,000 | +₩0.2bn | ₩-0.5bn | +₩0.3bn |
| 2026-08-28 | ₩66,000 | ₩-0.8bn | +₩0.1bn | +₩0.7bn |
| 2026-08-27 | ₩66,800 | +₩0.5bn | ₩-1.0bn | +₩0.5bn |
| 2026-08-26 | ₩68,200 | ₩-0.7bn | ₩-2.0bn | +₩2.7bn |
| 2026-08-25 | ₩70,700 | ₩-2.8bn | +₩1.8bn | +₩0.9bn |
| 2026-08-24 | ₩72,500 | +₩1.1bn | +₩5.5bn | ₩-6.6bn |
| 2026-08-21 | ₩62,000 | ₩-0.0bn | ₩-2.6bn | +₩2.6bn |
| 2026-08-20 | ₩71,700 | ₩-4.9bn | +₩3.8bn | +₩1.1bn |
| 2026-08-19 | ₩70,300 | +₩1.7bn | +₩6.2bn | ₩-8.1bn |
| 2026-08-18 | ₩65,700 | +₩2.9bn | ₩-1.4bn | ₩-1.5bn |
| 2026-08-14 | ₩68,100 | +₩1.0bn | ₩-0.4bn | ₩-0.5bn |
| 2026-08-13 | ₩66,900 | +₩0.1bn | ₩-0.1bn | +₩0.1bn |
| 2026-08-12 | ₩65,900 | +₩2.1bn | ₩-4.2bn | +₩2.4bn |
| 2026-08-11 | ₩71,000 | ₩-4.4bn | +₩3.9bn | +₩0.4bn |
| 2026-08-10 | ₩69,900 | ₩-4.1bn | +₩6.5bn | ₩-2.2bn |
| 2026-08-07 | ₩61,900 | ₩-1.2bn | +₩1.4bn | ₩-0.3bn |
| 2026-08-06 | ₩58,500 | ₩-1.9bn | +₩1.0bn | +₩0.9bn |
| 2026-08-05 | ₩59,000 | ₩-2.9bn | +₩1.4bn | +₩1.5bn |
| 2026-08-04 | ₩57,900 | ₩-6.1bn | +₩6.8bn | ₩-0.8bn |
| 2026-08-03 | ₩48,450 | ₩-0.1bn | +₩0.3bn | ₩-0.2bn |
| 2026-07-31 | ₩44,600 | +₩0.0bn | +₩0.3bn | ₩-0.3bn |
| 2026-07-30 | ₩37,800 | +₩0.2bn | +₩0.1bn | ₩-0.3bn |
| 2026-07-29 | ₩39,550 | ₩-0.2bn | +₩1.2bn | ₩-1.0bn |
| 2026-07-28 | ₩43,750 | ₩-0.3bn | +₩0.1bn | +₩0.2bn |
| 2026-07-27 | ₩47,450 | ₩-1.7bn | +₩1.3bn | +₩0.4bn |
| 2026-07-24 | ₩45,500 | +₩0.7bn | ₩-0.5bn | ₩-0.2bn |
| 2026-07-23 | ₩47,700 | ₩-0.7bn | +₩0.9bn | ₩-0.1bn |
| 2026-07-22 | ₩42,450 | +₩0.6bn | ₩-0.7bn | +₩0.1bn |
| 2026-07-21 | ₩41,900 | +₩0.4bn | +₩0.3bn | ₩-0.7bn |
| 2026-07-20 | ₩42,000 | +₩0.5bn | +₩0.0bn | ₩-0.5bn |
| 2026-07-16 | ₩45,400 | ₩-0.6bn | ₩-0.8bn | +₩1.3bn |
| 2026-07-15 | ₩48,400 | +₩0.4bn | +₩0.2bn | ₩-0.6bn |
| 2026-07-14 | ₩44,900 | +₩0.1bn | +₩0.4bn | ₩-0.4bn |
| 2026-07-13 | ₩45,400 | +₩0.4bn | ₩-0.6bn | +₩0.2bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩1.5bn | +$1M | +₩0.1bn | ₩-2.6bn |
| 5 days | +₩3.8bn | +$3M | ₩-2.7bn | ₩-2.8bn |
| 20 days | +₩4.5bn | +$3M | ₩-18.3bn | +₩14.5bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Orum Therapeutics stock?
Over the last 5 sessions foreign investors net bought ₩3.8bn ($3M) of Orum Therapeutics; over 60 sessions they net sold ₩9.6bn ($7M); since Jan 1, 2026 they net bought ₩36.7bn ($28M). Over 20 sessions the stock is the 78th largest foreign net purchase among 1828 KOSDAQ stocks.
How much of Orum Therapeutics do foreign investors own?
Foreign investors own 7.6% of Orum Therapeutics' shares as of Oct 13, 2026, versus 1.82% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩18.3bn ($14M) and retail investors net bought ₩14.5bn ($11M) of Orum Therapeutics. Foreign buying is being met mainly by institutional selling.
Is Orum Therapeutics listed on KOSPI or KOSDAQ?
Orum Therapeutics (오름테라퓨틱) trades on KOSDAQ under KRX code 475830 in the Biotech & Pharma group, with a market capitalization of ₩0T ($0.3B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2024 | ₩21bn ($16M) | – | -₩8bn (-$6M) | -₩6bn (-$4M) |
| 2025 | ₩0bn ($0M) | -99.90% | -₩52bn (-$39M) | -₩42bn (-$31M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.